Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD)

LEIDEN, Netherlands and LONDON, Jan. 13, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to dris­apersen and will retain rights to all oth­er pro­grams for the treat­ment of Duchenne Muscular Dystrophy (DMD). This trans­fer of rights rep­re­sents the ter­mi­na­tion of the col­lab­o­ra­tion agree­ment between GSK and Prosensa exe­cut­ed in 2009. Prosensa will now have the full, unen­cum­bered rights to con­tin­ue the devel­op­ment of dris­apersen as well as each of its DMD pro­grams.
The par­ties have agreed that Prosensa is well suit­ed to con­tin­ue the devel­op­ment of all of the DMD pro­grams. Prosensa and GSK have also agreed to make cer­tain data from the dris­apersen stud­ies avail­able in due course to the sci­en­tif­ic com­mu­ni­ty for the pur­pose of fur­ther­ing the gen­er­al under­stand­ing of DMD.
“We are ful­ly com­mit­ted to our mis­sion of devel­op­ing inno­v­a­tive, RNA-based ther­a­peu­tics to address unmet med­ical needs for patients with rare genet­ic dis­or­ders,” said Hans Schikan, Prosensa’s Chief Executive Officer. “Prosensa is now in a favor­able strate­gic posi­tion to advance the DMD port­fo­lio, which includes dris­apersen and five addi­tion­al com­pounds, three of which are cur­rent­ly in clin­i­cal devel­op­ment. We will con­tin­ue to work close­ly with patient groups, inves­ti­ga­tors, acad­e­mia and reg­u­la­tors to ensure that we do every­thing we can to bring treat­ments to boys affect­ed by DMD.”
“We have com­plet­ed our review and believe that fur­ther analy­sis of dris­apersen data may ben­e­fit from being viewed in the con­text of the body of infor­ma­tion which has been devel­oped by Prosensa through their work on addi­tion­al exon-skip­ping pro­grams. We great­ly val­ued the sci­en­tif­ic exper­tise that Prosensa pro­vid­ed since our col­lab­o­ra­tion start­ed in 2009.” said Dr Carlo Russo, Senior Vice President, Head of GSK Rare Diseases Research & Development. “We worked close­ly with Prosensa with the aim of devel­op­ing new med­i­cines to help boys with DMD and thanks to the ded­i­ca­tion of the boys and their fam­i­lies, we have gath­ered the largest clin­i­cal dataset relat­ed this con­di­tion. The val­ue of this data to the sci­en­tif­ic community’s under­stand­ing of DMD should not be under­es­ti­mat­ed, and we would like to thank every­one who par­tic­i­pat­ed in the stud­ies for their con­tri­bu­tions and patience as we worked through our analy­ses.”
Prosensa’s Schikan, added “GSK has been a valu­able devel­op­ment part­ner, and we are grate­ful for the com­mit­ment made by the com­pa­ny over the last four years to devel­op a dis­ease mod­i­fy­ing ther­a­py for this dev­as­tat­ing dis­ease. Together we have been able to progress the largest glob­al clin­i­cal pro­gram in DMD, and we have made tremen­dous progress in under­stand­ing the nat­ur­al his­to­ry and epi­demi­ol­o­gy of this rare and dev­as­tat­ing dis­ease. We look for­ward to updat­ing the com­mu­ni­ty with our plans as soon we are in a posi­tion to do so.”

Leave a Reply

Your email address will not be published. Required fields are marked *